Omega Fund Management LLC Has $7.80 Million Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Omega Fund Management LLC decreased its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 49.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,184,636 shares of the company's stock after selling 1,171,268 shares during the period. Lexeo Therapeutics accounts for approximately 6.5% of Omega Fund Management LLC's holdings, making the stock its 4th biggest holding. Omega Fund Management LLC owned 3.58% of Lexeo Therapeutics worth $7,795,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Janus Henderson Group PLC lifted its holdings in shares of Lexeo Therapeutics by 15.3% in the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company's stock valued at $28,508,000 after acquiring an additional 576,059 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Lexeo Therapeutics by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 567,383 shares of the company's stock valued at $3,735,000 after acquiring an additional 14,136 shares during the last quarter. Altium Capital Management LLC bought a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $2,665,000. DAFNA Capital Management LLC lifted its holdings in shares of Lexeo Therapeutics by 56.9% in the 4th quarter. DAFNA Capital Management LLC now owns 393,083 shares of the company's stock valued at $2,586,000 after acquiring an additional 142,500 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Lexeo Therapeutics by 7.1% in the fourth quarter. Northern Trust Corp now owns 214,284 shares of the company's stock worth $1,410,000 after purchasing an additional 14,185 shares during the last quarter. Institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Trading Up 20.0%

Shares of Lexeo Therapeutics stock traded up $0.54 on Friday, hitting $3.24. 1,738,822 shares of the company traded hands, compared to its average volume of 481,394. The stock's 50 day moving average price is $3.07 and its 200-day moving average price is $4.94. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics, Inc. has a 52 week low of $1.45 and a 52 week high of $19.50. The company has a market cap of $107.56 million, a PE ratio of -1.03 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.19). Equities research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on LXEO shares. Leerink Partners decreased their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research note on Monday, March 24th. Chardan Capital decreased their price objective on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Royal Bank of Canada decreased their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Finally, HC Wainwright decreased their price objective on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $20.20.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.